Remepy
Remepy is pioneering hybrid drugs, which are a new class of pharmaceutical assets that combine traditional drugs with proprietary software-based digital interventions. These "digital molecules" are therapeutic mobile apps designed to trigger physiological effects through the brain, thereby enhancing the effectiveness of conventional drugs. The company's approach redefines combination therapy by integrating software with drugs to create SaMD (Software as a Medical Device) drug combinations, enabling personalized treatment at scale. Remepy focuses on diseases where changes in brain connectivity, immune system modulation, and behavioral adjustments are synergistic with drug effects, with current areas of interest including Parkinson's Disease, Oncology, and Women's Health. They leverage AI-driven digital treatment protocols that adapt based on patient feedback, activity, and progress to optimize drug performance and address symptoms.
Remepy
Remepy is pioneering hybrid drugs, which are a new class of pharmaceutical assets that combine traditional drugs with proprietary software-based digital interventions. These "digital molecules" are therapeutic mobile apps designed to trigger physiological effects through the brain, thereby enhancing the effectiveness of conventional drugs. The company's approach redefines combination therapy by integrating software with drugs to create SaMD (Software as a Medical Device) drug combinations, enabling personalized treatment at scale. Remepy focuses on diseases where changes in brain connectivity, immune system modulation, and behavioral adjustments are synergistic with drug effects, with current areas of interest including Parkinson's Disease, Oncology, and Women's Health. They leverage AI-driven digital treatment protocols that adapt based on patient feedback, activity, and progress to optimize drug performance and address symptoms.